Identifying depression subtypes and investigating their consistency and transitions in a 1-year cohort analysis.

Major depressive disorder (MDD) is defined by an array of symptoms that make it challenging to understand the condition at a population level. Subtyping offers a way to unpick this phenotypic diversity for improved disorder characterisation. We aimed to identify depression subtypes longitudinally using the Inventory of Depressive Symptomatology: Self-Report (IDS-SR).

Skin and Soft Tissue Infection Complicated by Sepsis in an Immunocompromised Patient: A Rare Case Report.

Physicians should consider non-O1, non-O139 (NOVC) in the differential diagnosis of cellulitis complicated by sepsis, especially in immunocompromised patients when potential exposure exists. Due to the pathogen's potential for severe infections and rising incidence from environmental changes, we emphasize the need for increased awareness and appropriate treatment guidelines.

Incorporation of RLINE into AERMOD: An update and evaluation for mobile source applications.

The R-LINE model, which was released in 2013 as a stand-alone model for roadway-type applications and was based on a set of newly developed dispersion curves, exhibited favorable model performance in a limited set of evaluations. In 2019, the R-LINE model was incorporated as the RLINE source type in EPA's preferred near-field dispersion model AERMOD. Since its inclusion in AERMOD, the RLINE source type has been tested and compared to other AERMOD source types using multiple data sets and transportation studies.

Topiramate treatment of pediatric metabolic dysfunction-associated steatotic liver disease: A descriptive cohort study.

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common disease in children. Lifestyle modification is the primary treatment but difficult to achieve and maintain. Topiramate is a component of an approved weight loss medication (topiramate-phentermine) in children aged 12 years and older but is more commonly used as a single agent, off-label, for pediatric obesity.